MarketLens

What's Driving Rocket Pharmaceuticals' Latest FDA Review for KRESLADI

5 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Does the FDA's Priority Review Mean for Savara's MOLBREEVI

5 months ago

What's Driving Telix's Latest FDA Resubmission for Pixclara®

5 months ago

What Does the FDA's PDUFA Extension Signal for Rhythm Pharmaceuticals

5 months ago

What's Driving the Latest Market Volatility

5 months ago

Capricor shares skyrocket as FDA agrees to review new Duchenne drug data

Capricor Therapeutics shares more than doubled in premarket trading Friday after the FDA agreed to review new data on its experimental Duchenne muscular dystrophy drug, potentially accelerating a path...

CAPR

Stock News•5 days ago

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

Rocket Pharmaceuticals' Q2 earnings rose year over year, driven by Kresladi launch preparations and supportive RP-A501 safety findings that advance its development pipeline.

RCKT

Stock News•1 months ago

FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says

Regenxbio plans to refile its gene therapy application for a fatal brain disease after the FDA reversed its rejection and dropped placebo demands.

RGNX

Stock News•2 months ago

Why ImmunityBio Stock is Soaring Higher Today

ImmunityBio shares rose after the FDA accepted a review for a potential label expansion of its core drug, Anktiva. This regulatory milestone marks a critical step toward broadening the treatment's mar...

IBRX